SCHEMBL3536173

SCHEMBL3536173

COC(=O)c1c(OC)c(Br)cc2ncc(-c3ccc(C4CCCCC4)cc3)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.39
DHODH Q02127 2/20 0.39
STK17B O94768 2/20 0.38
STK17A Q9UEE5 1/20 0.38
ADORA3 P0DMS8 1/20 0.36
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
PARP1 P09874 1/20 0.35
S1PR1 P21453 2/20 0.34
DGAT1 O75907 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
HPGDS O60760 1/20 0.33
ACVR2A P27037 1/20 0.33
TGFBR2 P37173 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ABL1 P00519 1/20 0.33
TLR9 Q9NR96 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758623 0.83 NPC1 (0.41) HPGDDHODHADORA3PDGFRBPDGFRA
SCHEMBL3518631 0.83 SMN1; SMN2 (0.45) PDGFRBPARP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL3532730 0.79 DHODH (0.47) DHODHS1PR1DGAT1SMN1; SMN2ABL1
SCHEMBL3522253 0.79 PDGFRB (0.39) HPGDPDGFRBPDGFRAPARP1JAK2
SCHEMBL3520942 0.75 EGLN3 (0.42) DHODHS1PR1DGAT1
SCHEMBL3757203 0.73 ALPL (0.44) DHODHJAK2JAK1MAPT
SCHEMBL3518253 0.71 PDGFRB (0.39) HPGDPDGFRBPDGFRA
SCHEMBL3520739 0.71 SMN1; SMN2 (0.46) HPGDPDGFRBPARP1JAK2JAK1
SCHEMBL3517937 0.71 TSHR (0.37) HPGDHPGDSALDH1A1MAPTSMN1; SMN2
SCHEMBL3521595 0.68 MAPT (0.37) HPGDALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 HPGD 51/4885DHODH 20/4885STK17B 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.